How does the failure of Absorb apply to the other bioresorbable scaffolds? An expert review of first-in-man and pivotal trials
Yuki Katagiri(University of Amsterdam), Yoshinobu Onuma(Ollscoil na Gaillimhe – University of Galway), Yosuke Miyazaki(Yamaguchi University), Norihiro Kogame(Amsterdam UMC Location University of Amsterdam), Jan J. Piek(Amsterdam University Medical Centers), Taku Asano(Amsterdam UMC Location University of Amsterdam), Patrick W. Serruys(Erasmus MC), Ply Chichareon(Prince of Songkla University), Kuniaki Takahashi(University of Amsterdam), Rodrigo Modolo(Amsterdam UMC Location University of Amsterdam), Joanna J. Wykrzykowska(University Medical Center Groningen)
Cited by 23
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
|New England Journal of Medicine|2002|4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k